Every AI Intelligence Platform Asks the Market to Trust Its Numbers. Aimwell Partners Inc. (OTC:AIMN) Just Opened the Data

Rhea-AI Summary

Aimwell Partners (OTC:AIMN), parent of AimwellBio, launched a public AI intelligence signal feed at aimwellbio.com/signals. The feed exposes 419 regulatory, clinical, and research signals with no login or sales contact, allowing independent verification.

Signals span Phase II/III trials, FDA enforcement and recalls, peer‑reviewed research, and EMA safety/regulatory alerts. AimwellBio differentiates this public layer from its larger subscriber platform, publishes methodology, and offers observer access free to credentialed professionals, with subscriptions from $229/month.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

419 regulatory, clinical, and research signals are now publicly available at aimwellbio.com/signals-no login, no sales call, and no requirement to take the company's word for anything.

MIAMI, FL / ACCESS Newswire / July 6, 2026 / Aimwell Partners Inc. (OTC PINK:AIMN) - There is a test that very few AI intelligence companies can pass: show the data before the demo.

Most cannot.

The claims live in pitch decks. The metrics live in case studies that cannot be independently verified. The product sits behind an intake form, a sales sequence, or a non-disclosure agreement. The market is asked to trust first and verify later.

Aimwell Partners Inc. (OTC: AIMN), parent company of AimwellBio, has taken the opposite approach.

The company's public signal feed is now live at aimwellbio.com/signals, and it requires nothing to inspect-no login, no credentials, and no conversation with anyone.

What Is Visible Today

The public-tier feed currently displays 419 signals across four institutional source categories:

• 200 Phase II and Phase III clinical trial signals tracked from ClinicalTrials.gov and NIH registries on a scheduled refresh cycle.

• 69 FDA enforcement actions and recall alerts monitored from public U.S. Food and Drug Administration reporting.

• 150 peer-reviewed research signals indexed and scored from PubMed and NCBI biomedical literature.

• European Medicines Agency safety alerts, CHMP opinions, and regulatory decisions monitored on a scheduled refresh cycle.

Every figure can be counted by anyone who opens the page.

That is the point.

"The intelligence industry has trained buyers to accept claims that cannot be checked," said John Morgan, CEO of AimwellBio. "We think that era is ending, and we would rather end it ourselves than have it ended for us. The public feed is not a marketing asset. It is a standing invitation: come count."

The Distinction That Matters

The public feed is the visible layer-not the platform itself.

AimwellBio's full architecture continuously indexes a substantially larger corpus of regulatory and scientific intelligence across 13 independent institutional source streams, with cross-validation applied to every intelligence output before delivery to subscribers.

Platform capacity figures and methodology information are published at aimwellbio.com/press.

The company intentionally distinguishes between the two.

The 419-signal public feed represents what the market can verify today. The broader platform corpus represents the intelligence environment available to subscribers.

AimwellBio labels each accordingly and states plainly that public figures are launch-tier directional metrics that evolve as the platform matures and are not audited performance claims.

In a category where impressive numbers often disappear under diligence, the company that labels its metrics honestly is making a statement about everything else it publishes.

"A biopharma executive evaluating intelligence vendors should ask one question first," Morgan added. "Can I see the signal layer before I sign anything? If the answer is no, that tells you what you need to know. Our answer is a URL."

Why This Matters Now

Organizations across biopharma are increasingly making regulatory, clinical, and capital decisions informed by AI-generated intelligence while public enforcement activity continues to increase and regulators remain focused on health claim compliance and disclosure standards.

The cost of acting on unverifiable intelligence is no longer theoretical. It can appear as recalls, delayed filings, consent decrees, compliance failures, and board-level exposure.

AimwellBio's response is structural: source-traced outputs, adversarial validation, confidence labeling, and now a public evidence layer that allows professionals to inspect the signal stream before committing to anything.

The feed will continue to refresh on a scheduled cycle.

The numbers will change.

The invitation will not.

Access

The public signal feed is available now at aimwellbio.com/signals.

Observer-level platform access remains available at no cost to credentialed professionals. Individual subscriptions begin at $229 per month. Enterprise and institutional deployment inquiries may be submitted at aimwellbio.com/request-access.

The company's Adversarial Validation Standard is publicly available at aimwellbio.com/standard.

About Aimwell Partners Inc.

Aimwell Partners Inc. (OTC: AIMN) is the parent company of AimwellBio, a decision intelligence platform purpose-built for biopharmaceutical organizations. The platform continuously monitors regulatory, clinical, and competitive developments across 13 institutional source streams and synthesizes them into verified, hallucination-contained intelligence outputs for R&D leaders, regulatory affairs professionals, compliance teams, and life sciences investors.

More information is available at www.aimwellbio.com.

Media Contact
John Morgan, CEO
Aimwell Partners Inc.
corporate@aimwellbio.com
www.aimwellbio.com/press

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied herein. Aimwell Partners Inc. undertakes no obligation to update forward-looking statements except as required by law.

Signal counts referenced herein reflect the public-tier feed as of the date of publication and update on a scheduled refresh cycle. Platform capacity figures are directional launch-tier metrics and should not be interpreted as audited performance claims, realized client outcomes, or guarantees of future performance. AimwellBio provides analytical and informational outputs intended to support organizational decision-making and does not provide medical, legal, regulatory, or investment advice.

SOURCE: Aimwell Partners

View the original press release on ACCESS Newswire

FAQ

What is the AimwellBio public signal feed launched by Aimwell Partners (OTC:AIMN)?

The AimwellBio public signal feed is an online dashboard showing 419 AI-derived regulatory, clinical, and research signals. According to Aimwell, it lets users inspect real-time intelligence inputs without logins, demos, or sales calls, increasing transparency around its platform’s underlying data.

How many clinical, FDA, and research signals does AimwellBio show in its AIMN public feed?

AimwellBio’s public feed currently displays 419 signals across multiple categories. According to Aimwell, these include 200 Phase II/III clinical trial signals, 69 FDA enforcement and recall alerts, 150 peer-reviewed research signals, plus European Medicines Agency safety alerts and regulatory decisions.

How can investors and professionals access the AimwellBio AIMN signal feed and platform?

The public signal feed is accessible at aimwellbio.com/signals without registration. According to Aimwell, observer-level platform access is free for credentialed professionals, while individual subscriptions start at $229 per month, with enterprise deployments available via requests at aimwellbio.com/request-access.

Why does the AimwellBio AIMN public feed matter for biopharma decision-makers?

The feed provides source-traced regulatory and clinical signals that users can independently count and inspect. According to Aimwell, this supports decisions in an environment of rising enforcement, health-claim scrutiny, and growing reliance on AI-generated intelligence across biopharma organizations.

What is AimwellBio’s Adversarial Validation Standard and how does it relate to AIMN’s platform?

AimwellBio’s Adversarial Validation Standard describes its approach to stress-testing AI-generated outputs. According to Aimwell, it applies cross-validation and confidence labeling to regulatory and scientific intelligence, and publishes this standard publicly at aimwellbio.com/standard for prospective subscribers and stakeholders.

How does the AimwellBio AIMN public feed differ from its full intelligence platform?

The public feed shows a launch-tier subset of signals that anyone can verify. According to Aimwell, the full platform indexes a substantially larger corpus from 13 institutional sources, with cross-validated outputs delivered only to paying subscribers and institutional clients.